Revvity (RVTY) Stock May Be Fairly Priced Following A Cell Model Deal

Revvity has produced a sharp share price run, and the question now is whether the current valuation lines up with the cash it is expected to generate. After such a move, the key issue for you is whether the recent price action reflects fundamentals or stretches too far beyond what the business may reasonably earn over time.

• Revvity has delivered a 71.1% return over the past year, which puts a lot of pressure on its cash flow outlook to justify the higher price tag.
• The pending acquisition of Human Cell Design, with its focus on human cell models for metabolic disease research, can influence expectations for future cash generation and investment needs as Revvity builds out this part of the business.
• Prefer to judge Revvity on earnings? See why Revvity's 68.5x P/E tells a different valuation story.

The issue now is whether the cash flows implied by Revvity's current share price are consistent with what a Discounted Cash Flow (DCF) intrinsic value estimate suggests.

If you want a clearer yardstick for Revvity's recent run and the Human Cell Design deal, line it up against 33 high quality undervalued stocks.

Where Does Revvity Sit on Cash Flow?

The Discounted Cash Flow (DCF) approach looks at what Revvity might generate in cash and then compares that to the current market price. Revvity has produced latest twelve month free cash flow of about $545.6 million, and the DCF model assumes those owner earnings continue to grow from that base rather than shrink away. That profile suits a business that is already throwing off cash but still being asked to invest for its next phase.

Analyst projections in the model point to rising free cash flow over the coming decade, followed by a second stage where growth moderates. Together, these assumptions result in an estimated intrinsic value that is broadly in line with the current $145.73 share price. Because the planned Human Cell Design acquisition adds another cash-hungry growth project to the mix, the fact the DCF output roughly matches where the market is trading suggests investors are already baking that ambition into expectations. Find out what Revvity could be worth using our Discounted Cash Flow (DCF) estimate.

The Revvity Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Revvity valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to unfold for the stock to be worth meaningfully more or less than today. Each scenario attaches a fair value to a specific mix of potential catalysts and risks, so you can track over time which description of Revvity's future seems closest to reality on the Community page.

Revvity brings out two quite different community takes, with one group seeing more runway in genomics and software while another worries the price already bakes in a lot of good news.

Bull case: 8% undervalued

"Revvity's early leadership here could unlock an outsized, multi-year acceleration in reproductive health and rare disease diagnostics, driving both revenue and margin expansion well beyond current expectations..."

Discover why this Narrative puts Revvity at 8% undervalued.

Bear case: 20% overvalued

"The company's reliance on structural cost actions, share buybacks, and the absence of compelling acquisition targets may provide short-term EPS support, but could limit strategic investment in growth initiatives and innovation..."

Explore why this Narrative puts Revvity at 20% overvalued.

The unresolved question for Revvity investors

Revvity's valuation story only goes so far, because separate checks have flagged concerns that deserve your attention before you lean too heavily on the cash flow profile. Take a closer look at 1 warning sign before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com